Chronic Lymphocytic Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Lymphocytic Leukemia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-08-31FDA Approved: LENALIDOMIDE — Original Application (Alvogen, Inc.)
FDA approved the original application for Lenalidomide from Alvogen, Inc., enabling a generic version of lenalidomide to enter the market.
-
FDA approval · 2022-08-30FDA Approved: LENALIDOMIDE — Original Application (Mylan Pharmaceuticals Inc.)
FDA approved lenalidomide as an original application for Mylan Pharmaceuticals Inc., establishing a generic version of lenalidomide.
-
FDA approval · 2022-08-24FDA Approved: IMBRUVICA — Supplemental Application (Pharmacyclics LLC)
The FDA approved a supplemental application for IMBRUVICA (ibrutinib) submitted by Pharmacyclics LLC.
-
CLINICAL_TRIALS trial_result · 2022-08-04Clinical Trial Update: Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL [Phase 1, Phase 2]
Phase 1/2 trial evaluating KRT-232 in combination with acalabrutinib for relapsed/refractory DLBCL and CLL; status not disclosed.
-
CLINICAL_TRIALS trial_result · 2022-08-02Clinical Trial Update: A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations [Phase 2]
Phase II multicenter trial evaluating the combination of ibrutinib and venetoclax in relapsed/refractory chronic lymphocytic leukemia with a…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-07-20Clinical Trial Update: Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL [Phase 2]
A Phase 2 trial evaluating the combination of lenalidomide and azacitidine for relapsed/refractory chronic lymphocytic leukemia and small ly…
-
FDA approval · 2022-07-06FDA Approved: ZYDELIG — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for ZYDELIG (idelalisib) submitted by Gilead Sciences, Inc. The specific changes to the product'…
-
CLINICAL_TRIALS trial_result · 2022-07-06Clinical Trial Update: A Study to Evaluate ICP-022 in Patients With CLL/ SLL [Phase 1, Phase 2]
Clinical trial update on ICP-022 for chronic lymphocytic leukemia and small lymphocytic lymphoma (early-phase study).
-
FDA label_change · 2022-06-30FDA Approved: LENALIDOMIDE — Supplemental Application (Dr. Reddy's Laboratories Inc.)
FDA approved a supplemental application for lenalidomide submitted by Dr. Reddy's Laboratories Inc., resulting in updated labeling for the d…
-
FDA approval · 2022-06-03FDA Approved: RIABNI — Supplemental Application (Amgen, Inc)
FDA approved a supplemental application for RIABNI (rituximab-arrx) from Amgen. The action updates RIABNI’s labeling to reflect its approved…
-
CLINICAL_TRIALS trial_result · 2022-05-25Clinical Trial Update: Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia [Phase 1, Phase 2]
Phase 1/2 trial evaluating laboratory-treated T cells in relapsed or refractory B-cell malignancies and acute lymphoblastic leukemia.
-
CLINICAL_TRIALS trial_result · 2022-05-20Clinical Trial Update: Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) [Phase 3]
Phase 3 trial comparing ublituximab plus ibrutinib versus ibrutinib alone in previously treated high-risk chronic lymphocytic leukemia has c…
-
FDA approval · 2022-05-11FDA Approved: IMBRUVICA — Supplemental Application (Pharmacyclics LLC)
FDA approved a supplemental application for IMBRUVICA (ibrutinib) from Pharmacyclics LLC.
-
FDA approval · 2022-05-11FDA Approved: IMBRUVICA — Supplemental Application (Pharmacyclics LLC)
FDA approves a supplemental application for IMBRUVICA (ibrutinib) submitted by Pharmacyclics LLC. The document indicates FDA approval of the…
-
CLINICAL_TRIALS trial_result · 2022-05-10Clinical Trial Update: Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma [Phase 1]
Phase 1 trial evaluating safety and tolerability of brexucabtagene autoleucel (KTE-X19) in relapsed/refractory chronic lymphocytic leukemia …
-
CLINICAL_TRIALS trial_result · 2022-05-06Clinical Trial Update: Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation [Phase 2]
Phase 2 clinical trial evaluating adding ofatumumab to reduced intensity conditioning for high-risk chronic lymphocytic leukemia patients un…
-
CLINICAL_TRIALS trial_result · 2022-05-06Clinical Trial Update: ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies [Phase 1, Phase 2]
Phase 1/2 trial of acalabrutinib (ACP-196) in combination with pembrolizumab in hematologic malignancies has completed with results posted i…
-
CLINICAL_TRIALS trial_result · 2022-04-19Clinical Trial Update: Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL [Phase 2]
Phase 2 trial update evaluating orelabrutinib with obinutuzumab plus FC in newly diagnosed CLL/SLL.
-
CLINICAL_TRIALS trial_result · 2022-04-11Clinical Trial Update: Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]
Phase 2 trial investigating bendamustine and rituximab in combination with copanlisib for chronic lymphocytic leukemia or small lymphocytic …
-
CLINICAL_TRIALS trial_result · 2022-04-05Clinical Trial Update: Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL [Phase 1, Phase 2]
Phase 1/2a dose-escalation study in CLL/SLL and various NHL subtypes completed with results posted.
-
CLINICAL_TRIALS trial_result · 2022-03-31Clinical Trial Update: Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL [Phase 2]
Phase 2 trial evaluating zanubrutinib followed by zanubrutinib plus FCR/BR in newly diagnosed symptomatic CLL/SLL.
-
CLINICAL_TRIALS trial_result · 2022-03-28Clinical Trial Update: A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) [Phase 3]
This Phase 3 clinical trial update reports results for frontline therapy in chronic lymphocytic leukemia/small lymphocytic lymphoma comparin…
-
CLINICAL_TRIALS trial_result · 2022-03-28Clinical Trial Update: A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) [Phase 3]
Phase 3 trial evaluating ibrutinib plus venetoclax versus chlorambucil plus obinutuzumab as first-line therapy in chronic lymphocytic leukem…
-
FDA approval · 2022-03-10FDA Approved: ZYDELIG — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for ZYDELIG (idelalisib) from Gilead Sciences, Inc. The action updates the labeling for the drug…
-
CLINICAL_TRIALS trial_result · 2022-03-10Clinical Trial Update: Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia [Phase 1]
Phase 1 trial evaluating human IL-15 and obinutuzumab in relapsed/refractory chronic lymphocytic leukemia was terminated with posted results…